Marc Stapley Sells 2,000 Shares of Illumina, Inc. (ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $216.87, for a total transaction of $433,740.00. Following the completion of the transaction, the executive vice president now directly owns 27,952 shares of the company’s stock, valued at approximately $6,061,950.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Marc Stapley also recently made the following trade(s):

  • On Wednesday, January 17th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $242.33, for a total transaction of $484,660.00.
  • On Monday, December 4th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $219.88, for a total transaction of $439,760.00.
  • On Wednesday, November 15th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $205.48, for a total transaction of $410,960.00.

Illumina, Inc. (NASDAQ ILMN) traded down $11.66 on Thursday, reaching $209.54. 1,292,756 shares of the company’s stock traded hands, compared to its average volume of 1,020,000. The company has a current ratio of 3.99, a quick ratio of 3.55 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 12 month low of $158.02 and a 12 month high of $248.97. The stock has a market capitalization of $30,590.00, a P/E ratio of 42.50, a P/E/G ratio of 2.92 and a beta of 0.92.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.22. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The company had revenue of $778.00 million during the quarter, compared to the consensus estimate of $752.04 million. During the same period in the previous year, the firm earned $0.85 earnings per share. Illumina’s revenue for the quarter was up 25.7% on a year-over-year basis. equities research analysts anticipate that Illumina, Inc. will post 4.59 EPS for the current year.

A number of research firms recently issued reports on ILMN. Canaccord Genuity restated a “buy” rating and issued a $230.00 target price (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. Deutsche Bank upgraded shares of Illumina from a “hold” rating to a “buy” rating and lowered their target price for the company from $195.00 to $160.00 in a report on Monday, October 23rd. Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a report on Monday, October 23rd. Robert W. Baird upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $184.00 to $228.00 in a report on Wednesday, October 25th. Finally, Wells Fargo & Co restated a “market perform” rating and issued a $205.00 target price (up from $200.00) on shares of Illumina in a report on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $241.39.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board grew its stake in Illumina by 19.2% during the fourth quarter. State of Wisconsin Investment Board now owns 185,505 shares of the life sciences company’s stock worth $40,531,000 after buying an additional 29,943 shares during the period. Global X Management Co. LLC grew its stake in Illumina by 61.5% during the fourth quarter. Global X Management Co. LLC now owns 4,150 shares of the life sciences company’s stock worth $907,000 after buying an additional 1,581 shares during the period. Toronto Dominion Bank grew its stake in Illumina by 13.6% during the fourth quarter. Toronto Dominion Bank now owns 62,891 shares of the life sciences company’s stock worth $13,740,000 after buying an additional 7,511 shares during the period. The Manufacturers Life Insurance Company grew its stake in Illumina by 0.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 156,610 shares of the life sciences company’s stock worth $34,218,000 after buying an additional 1,292 shares during the period. Finally, Barings LLC purchased a new stake in Illumina during the fourth quarter worth approximately $767,000. Institutional investors own 92.09% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/08/marc-stapley-sells-2000-shares-of-illumina-inc-ilmn-stock.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply